These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 19636696

  • 1. Covert use, vaginal lubrication, and sexual pleasure: a qualitative study of urban U.S. Women in a vaginal microbicide clinical trial.
    Hoffman S, Morrow KM, Mantell JE, Rosen RK, Carballo-Diéguez A, Gai F.
    Arch Sex Behav; 2010 Jun; 39(3):748-60. PubMed ID: 19636696
    [Abstract] [Full Text] [Related]

  • 2. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study.
    Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, Maslankowski L, El-Sadr WM, Mayer KH.
    J Womens Health (Larchmt); 2008 Apr; 17(3):383-92. PubMed ID: 18328009
    [Abstract] [Full Text] [Related]

  • 3. Young Women's use of a microbicide surrogate: the complex influence of relationship characteristics and perceived male partners' evaluations.
    Tanner AE, Fortenberry JD, Zimet GD, Reece M, Graham CA, Murray M.
    Arch Sex Behav; 2010 Jun; 39(3):735-47. PubMed ID: 19224355
    [Abstract] [Full Text] [Related]

  • 4. Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.
    Doggett EG, Lanham M, Wilcher R, Gafos M, Karim QA, Heise L.
    J Int AIDS Soc; 2015 Jun; 18(1):20536. PubMed ID: 26700845
    [Abstract] [Full Text] [Related]

  • 5. Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting.
    Vallely A, Fitzgerald L, Fiya V, Aeno H, Kelly A, Sauk J, Kupul M, Neo J, Millan J, Siba P, Kaldor JM.
    BMC Res Notes; 2012 Nov 01; 5():613. PubMed ID: 23116431
    [Abstract] [Full Text] [Related]

  • 6. A comparison of young women's actual and assigned timing of use of a microbicide surrogate.
    Tanner AE, Roof KA, Katz BP, Katschke A, Fortenberry JD, Zimet GD.
    Sex Health; 2012 Sep 01; 9(4):299-303. PubMed ID: 22877587
    [Abstract] [Full Text] [Related]

  • 7. Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial.
    Succop SM, MacQueen KM, van Loggerenberg F, Majola N, Karim QA, Karim SS.
    AIDS Care; 2014 Sep 01; 26(12):1521-5. PubMed ID: 25285564
    [Abstract] [Full Text] [Related]

  • 8. Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand.
    Jones HE, Chaikummao S, van de Wijgert JH, Friedland BA, Manopaiboon C, Witwatwongwana P, Wankrairot M, Chantharojwong N, Kilmarx PH.
    J Womens Health (Larchmt); 2009 Jul 01; 18(7):1003-10. PubMed ID: 19575689
    [Abstract] [Full Text] [Related]

  • 9. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
    Karim QA, Kharsany AB, Frohlich JA, Baxter C, Yende N, Mansoor LE, Mlisana KP, Maarschalk S, Arulappan N, Grobler A, Sibeko S, Omar Z, Gengiah TN, Mlotshwa M, Samsunder N, Karim SS.
    Trials; 2011 Mar 07; 12():67. PubMed ID: 21385354
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004 Trial Group.
    Science; 2010 Sep 03; 329(5996):1168-74. PubMed ID: 20643915
    [Abstract] [Full Text] [Related]

  • 11. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial.
    Sokal DC, Karim QA, Sibeko S, Yende-Zuma N, Mansoor LE, Baxter C, Grobler A, Frolich J, Kharsany AB, Miya N, Mlisana K, Maarshalk S, Karim SS.
    Antivir Ther; 2013 Sep 03; 18(3):301-10. PubMed ID: 22914267
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana.
    Abdulai MA, Baiden F, Adjei G, Afari-Asiedu S, Adjei K, Tawiah C, Newton S.
    BMC Womens Health; 2012 Nov 01; 12():40. PubMed ID: 23114222
    [Abstract] [Full Text] [Related]

  • 14. Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa.
    Miller L, Morar N, Kapiga S, Ramjee G, Hayes R.
    J Acquir Immune Defic Syndr; 2020 Dec 01; 85(4):458-465. PubMed ID: 33136745
    [Abstract] [Full Text] [Related]

  • 15. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing.
    Braunstein S, van de Wijgert J.
    J Womens Health (Larchmt); 2005 Jun 01; 14(5):424-33. PubMed ID: 15989415
    [Abstract] [Full Text] [Related]

  • 16. Educating men about vaginal microbicides: considerations from Kenya.
    Gitome SW, Kwena ZA, Harper CC, Cohen CR, Bukusi EA.
    Cult Health Sex; 2020 Jun 01; 22(6):660-674. PubMed ID: 31241426
    [Abstract] [Full Text] [Related]

  • 17. To tell or not to tell: male partner engagement in a Phase 3 microbicide efficacy trial in South Africa.
    Kelly CA, Friedland BA, Morar NS, Katzen LL, Ramjee G, Mokgatle MM, Ahmed K.
    Cult Health Sex; 2015 Jun 01; 17(8):1004-20. PubMed ID: 25913101
    [Abstract] [Full Text] [Related]

  • 18. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.
    Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, Morar N, Maslankowski L, Profy AT, Kelly C, Abdool Karim SS, Mayer KH.
    J Womens Health (Larchmt); 2003 Sep 01; 12(7):655-66. PubMed ID: 14583106
    [Abstract] [Full Text] [Related]

  • 19. Sexuality, HIV risk and potential acceptability of involving adolescent girls in microbicide research in Kisumu, Kenya.
    Montandon M, Sahin-Hodoglugil NN, Bukusi E, Agot K, Boland B, Cohen CR.
    Sex Health; 2008 Dec 01; 5(4):339-46. PubMed ID: 19061553
    [Abstract] [Full Text] [Related]

  • 20. Vaginal deployment and tenofovir delivery by microbicide gels.
    Gao Y, Yuan A, Chuchuen O, Ham A, Yang KH, Katz DF.
    Drug Deliv Transl Res; 2015 Jun 01; 5(3):279-94. PubMed ID: 25874971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.